Pharmacogenetic testing helps tailor medication choices to each patient’s genetic profile.
By identifying genetic risks, clinicians can avoid drugs likely to cause adverse reactions and improve patient safety.
Choosing suitable medication first time speeds up recovery and reduces the need for trial-and-error adjustments.
Test results remain valid for life, supporting informed prescribing decisions across all future treatments.
Abomics is now part of the Fingenious Ecosystem, bringing the company closer to Finland’s biobank network and research-grade genetic data. This collaboration opens opportunities to use this data to support more personalized medication decisions.
Mikko Välimäki has been appointed to Abomics’ Board of Directors, while Ari Hakkarainen has concluded his term. Välimäki brings extensive experience in technology companies, entrepreneurship, and international growth, strengthening the Board’s work in supporting the company’s long-term development.
Abomics has appointed a new Lead Bioinformatician to deepen its expertise in genomics and pharmacogenetics. The role strengthens scientific capabilities behind clinically actionable solutions and supports the practical implementation of precision medicine in healthcare settings.
Whether you have a question, idea, or feedback, please fill out the form to send us a message.